Dr.Raj Vardhan AzadĀ [A02248] – New Delhi
Rising cost of medicine is a prohibiting factor for availing quality health care for large population of our country; more so true for more than 30% of the ageing population. Age-related macular degeneration (AMD) is one of the common vision disorder which leads to blindness if left to nature. Introduction of anti-VEGF has proved to be a boon for such patients but cost of treatment leaves large no of patients going untreated or partially treated due to poor sustenance.
| 1 | Current practice in the management of AMD. (10 mins) | Dr.Dinesh Talwar | watch video |
| 2 | Rationale of tailored approach ? (10 mins) | Dr.Bhuvan Chanana | watch video |
| 3 | Biosimilars of Bevacizumab (Zybev, Avastin) – cost and efficacy as monotherapy and tailored therapy. (10 mins | Dr.Giridhar Anantharaman | watch video |
| 4 | DISHA Experience of Razumab ( Analysis of > 1000 Patients( 10mins ) | Dr. Debdulal Chakraborty | watch video |
| 5 | Aflibercept: cost and efficacy (10 mins) | Dr.Shobhit Chawla | watch video |
| 6 | What should be the pragmatic approach to Anti-VEGF for all as a sustainable option (15 mins) | Dr.Raj Vardhan Azad | watch video |
| 7 | Keynote Address by : Relationship Between Drusen Characteristics andType 2 Macular Neovascularization in Age-Related Macular Degeneration ( 10 mins ) | Dr.Daniel Ahmed | watch video |
| Panel Discussion : (10 mins.) |


Leave a Comment